The present invention relates to a novel DNA delivery vector for targeted gene therapy, medical imaging and vaccination with increased efficacy over existing technologies. The platform comprises a phagemid hybrid with phage and recombinant adeno-associated virus (AAV) components.
Novel truncated fragments of von Willebrand factor (VWF) engineered by a team at Imperial College London.
Functionalised graphene for use as a nucleant
Lactobacillus ST peptide for therapeutic use against inflammatory bowel disease
Dr Mark Isalan – Reader in Gene Network Engineering at Imperial College London – and collaborators have developed a novel gene therapy for Huntington’s Disease that leverages zinc finger protein technology.